Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2000
03/16/2000WO2000014198A2 Isolation of human pemt2 gene and methods for diagnosing and treating liver disorders
03/16/2000WO2000014118A1 Ozf protein-specific monoclonal antibodies and their diagnostic therapeutic uses
03/16/2000WO2000014117A1 Peptide ligands for affinity purification of human factor viii
03/16/2000WO2000014116A1 T cell peptides as therapeutics for immune-related disease
03/16/2000WO2000014114A1 Peptide fragments of cholera toxin b or enterotoxin b as vaccine adjuvants
03/16/2000WO2000014113A2 Method of stimulating prosaposin receptor activity
03/16/2000WO2000014112A2 Papillomaviruses, means for the detection thereof and therapy for diseases caused thereby
03/16/2000WO2000014111A1 Novel physiologically active substances and process for producing the same
03/16/2000WO2000014110A1 CRYSTALLINE FORMS OF EtO2C-CH2-(R)Cgl-Aze-Pab-OH
03/16/2000WO2000014109A1 Basic products having antagonistic activity on the nk-1 receptor and their use in pharmaceutical compositions
03/16/2000WO2000014106A1 Novel bag proteins and nucleic acid molecules encoding them
03/16/2000WO2000013710A2 Hydrogel compositions for the controlled release administration of growth factors
03/16/2000WO2000013708A1 Methods for treating or preventing viral infections and associated diseases
03/16/2000WO2000013707A1 Preventives/remedies for multiple organ failure
03/16/2000WO2000013706A1 Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
03/16/2000WO2000013705A1 Use of tgf-beta inhibitors for treating cerebral disorders
03/16/2000WO2000013703A2 Methods of treating hypertension and compositions for use therein
03/16/2000WO2000013702A2 Use of an angiogenic factor for the treatment of microvascular angiopathies
03/16/2000WO2000013701A2 Angiogenically effective unit dose of fgf-2 and method of use
03/16/2000WO2000013700A1 Method of using fetuin to induce apoptosis in cancer cells
03/16/2000WO2000013699A1 An antigenic peptide encoded by an alternative open reading frame of human macrophage colony-stimulating factor
03/16/2000WO2000013694A1 Gcp
03/16/2000WO2000013689A1 Methods and compositions for increasing intestinal absorption of fats
03/16/2000WO2000013683A2 Novel nitrophenylaziridine compounds and their use as prodrugs
03/16/2000WO2000013677A1 Nanogel networks and biological agent composition thereof
03/16/2000WO2000013674A1 Dosage form comprising therapeutic formulation
03/16/2000WO2000013671A1 Immediate release tablet
03/16/2000WO2000013652A2 Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin
03/16/2000WO2000013650A2 Neuroprotection
03/16/2000WO2000013529A1 Foods for preventing vomiting
03/16/2000WO2000013501A1 Improved artificial blood fluids
03/16/2000WO2000006696A3 Method for the modulation of function of transcription factors
03/16/2000WO2000006694A3 Compound and method for the prevention and/or the treatment of allergy
03/16/2000WO2000003005A3 Human checkpoint kinase
03/16/2000WO2000002897A3 Delta cleavage products and methods based thereon
03/16/2000WO2000002582A3 Treatment of celiac disease with interleukin-15 antagonists
03/16/2000WO2000000621A8 Adh7 nucleotides
03/16/2000WO1999067391A9 Origin of replication and methods of use
03/16/2000WO1999067286A3 Novel staphylococcus peptides for bacterial interference
03/16/2000WO1999064598A3 Novel insulin analogs with enhanced zinc binding
03/16/2000WO1999064047A9 Novel antiviral compounds
03/16/2000WO1999063929A9 Multibinding inhibitors of microsomal triglyceride transferase protein
03/16/2000WO1999062939A3 Glycoproteins having lipid mobilising properties and therapeutic applications thereof
03/16/2000WO1999062927A9 Connective tissue growth factor-4
03/16/2000WO1999061471A3 Human transmembrane proteins
03/16/2000WO1999058570A3 Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis
03/16/2000WO1999058559B1 Factors affecting tumor necrosis factor receptor releasing enzyme activity
03/16/2000WO1999057151A3 FAP α-SPECIFIC ANTIBODY WITH IMPROVED PRODUCIBILITY
03/16/2000WO1999053064A3 Methods of delivering glp-1
03/16/2000WO1999050403A9 Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses
03/16/2000WO1999046385A3 Compositions and methods for the treatment and prevention of metastatic disorders
03/16/2000WO1999012561A9 FRACTURE HEALING USING PTHrP ANALOGS
03/16/2000DE19845434C1 Tissue binding peptides and related nucleotide sequences useful for tissue specific gene transfer
03/16/2000DE19841698A1 Composition for accelerating healing of tissue damage in cartilage or wounds, comprises thrombocyte growth factor, fibrin or fibrinogen and polymer
03/16/2000CA2349210A1 Cyclic nucleotide-associated proteins
03/16/2000CA2345895A1 Improved artificial blood fluids
03/16/2000CA2345050A1 Method of using fetuin to induce apoptosis in cancer cells
03/16/2000CA2343522A1 Methods for treating or preventing viral infections and associated diseases
03/16/2000CA2343351A1 Human transferase proteins
03/16/2000CA2343214A1 Neuroprotection
03/16/2000CA2343156A1 Fusion receptors specific for prostate-specific membrane antigen and uses thereof
03/16/2000CA2342984A1 Recombinant human sm-11044-binding receptor protein having activity of binding to ligand and utilization thereof
03/16/2000CA2342963A1 Ozf protein-specific monoclonal antibodies and their diagnostic therapeutic uses
03/16/2000CA2342943A1 Novel nitrophenylaziridine compounds and their use as prodrugs
03/16/2000CA2342800A1 Nanogel networks and biological agent composition thereof
03/16/2000CA2342796A1 Preventives/remedies for multiple organ failure
03/16/2000CA2342792A1 Enzymatic oxidative deamination process
03/16/2000CA2342280A1 Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
03/16/2000CA2342208A1 Use of tgf-beta inhibitors for treating cerebral disorders
03/16/2000CA2342070A1 Grf analogs with increased biological potency
03/16/2000CA2342027A1 Novel bag proteins and nucleic acid molecules encoding them
03/16/2000CA2341782A1 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus
03/16/2000CA2341777A1 Neutral amino acid transporter and gene thereof
03/16/2000CA2341326A1 Novel protein and process for producing the same
03/16/2000CA2341325A1 Method of stimulating prosaposin receptor activity
03/16/2000CA2341302A1 Lim domain protein homolog
03/16/2000CA2341259A1 Crystalline forms of eto2c-ch2-(r)cgl-aze-pab-oh
03/16/2000CA2341149A1 Hypertension associated transcription factor-1 (hatf-1) and hatf related protein 1 (hrp-1)
03/16/2000CA2338384A1 Peptide fragments of cholera toxin b or enterotoxin b as vaccine adjuvants
03/15/2000EP0985729A2 Streptokinase mutants
03/15/2000EP0985412A2 Cyclosporin compositions
03/15/2000EP0985149A1 Methods for evaluating tissue morphogenesis and activity
03/15/2000EP0985052A1 METHODS AND COMPOSITIONS TO IDENTIFY SWINE GENETICALLY RESISTANT TO F18 $i(E. COLI) ASSOCIATED DISEASES
03/15/2000EP0985046A1 A soluble vaccinia virus protein that binds chemokines
03/15/2000EP0985045A2 Modulators of morphogen expression and methods of identifying the same
03/15/2000EP0985040A1 Preparation of glycosylated tumor necrosis factor
03/15/2000EP0985038A1 Sodium channel receptor
03/15/2000EP0985037A1 Human multiple endocrine neoplasia type 1 protein
03/15/2000EP0985036A1 Zinc ring protein
03/15/2000EP0985035A2 Dna methyltransferase genomic sequences and antisense oligonucleotides
03/15/2000EP0985030A2 New human ribonuclease
03/15/2000EP0985028A2 Transplants for myocardial scars and method and cellular preparations therefor
03/15/2000EP0984987A2 A soluble laminin receptor precursor and methods to ihnibit its interactions
03/15/2000EP0984986A2 Human type 3 ryanodine receptor protein and dna molecules coding therefor
03/15/2000EP0984984A2 HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
03/15/2000EP0984983A2 Modulators of intracellular inflammation, cell death and cell survival pathways containing a card and a kinase domain
03/15/2000EP0984982A1 Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them
03/15/2000EP0984981A1 Anti-inflammatory tyrosine derivatives
03/15/2000EP0984790A1 Herpes simplex virus vp22 vaccines and methods of use
03/15/2000EP0984789A2 Accelerating animal hoof growth with somatotropin
1 ... 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 ... 3163